Kamada Ltd.

KMDA ·Healthcare, Drug Manufacturers - General, Israel
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $180.5M $161.0M $142.5M $129.3M $103.6M $133.2M $127.2M $114.5M
Cost of Revenue $104.1M $91.0M $87.0M $82.6M $73.3M $85.7M $77.5M $73.0M
Gross Profit $76.4M $70.0M $55.5M $46.7M $30.3M $47.6M $49.7M $41.5M
Gross Margin 42.3% 43.5% 38.9% 36.1% 29.3% 35.7% 39.1% 36.2%
Operating Expenses
Research & Development — — — — — — — —
SG&A Expense — — — — — $10.1M $9.2M $8.5M
Operating Income $26.2M $20.1M $10.1M $4.5M $-696.0K $19.2M $22.8M $19.3M
Operating Margin 14.5% 12.5% 7.1% 3.5% -0.7% 14.4% 17.9% 16.8%
Interest Expense — — — — — — — —
Pretax Income $23.5M $13.3M $8.4M $-2.3M $-1.9M $18.6M $23.0M $20.3M
Income Tax Expense $3.3M $-1.1M $145.0K $62.0K $345.0K $1.4M $730.0K $-2.0M
Net Income $20.2M $14.5M $8.3M $-2.3M $-2.2M $17.1M $22.3M $22.3M
Net Margin 11.2% 9.0% 5.8% -1.8% -2.2% 12.9% 17.5% 19.5%
EPS (Basic) $0.35 $0.25 $0.17 $-0.05 $-0.05 $0.39 $0.55 $0.55
EPS (Diluted) $0.35 $0.25 $0.15 $-0.05 $-0.05 $0.38 $0.55 $0.55
Shares Outstanding (Basic) 57.7M 57.5M 57.5M 44.8M 44.8M 44.7M 4.0M 40.3M
Shares Outstanding (Diluted) 57.7M 57.5M 57.5M 44.8M 44.8M 44.7M 4.0M 40.3M
Dividends Per Share — — — — — — — —
← Newer Page 1 of 2 Older →